Unity Confirm Launches Non-Invasive Prenatal Testing Breakthrough
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: PRnewswire
- Technological Breakthrough: BillionToOne has launched Unity Confirm™, which utilizes its Fetal Cell Capture™ technology to non-invasively capture intact fetal cells, achieving a 100% fetal fraction and significantly enhancing the accuracy and accessibility of prenatal testing.
- Clinical Validation: Unity Confirm demonstrated 100% concordance with known fetal outcomes and invasive diagnostic results across 16 samples, providing a reliable non-invasive confirmation solution for high-risk prenatal screenings and reducing pregnancy risks.
- Market Demand: As non-invasive prenatal testing (NIPT) becomes the standard, Unity Confirm offers a new option for patients who cannot or choose not to undergo invasive testing, bridging the information gap between screening and diagnosis and improving healthcare equity.
- Future Research: BillionToOne is enrolling 1,000 patients in a prospective study to further validate the performance of Unity Confirm, which is expected to have a profound impact on the field of prenatal genetic testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLLN
Wall Street analysts forecast BLLN stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 97.800
Low
110.00
Averages
137.83
High
160.00
Current: 97.800
Low
110.00
Averages
137.83
High
160.00
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adams Street Partners Exits Entire Paymentus Stake for $5.9 Million
- Share Sale Details: Adams Street Partners LLC reported in its SEC filing dated May 15, 2026, that it sold its entire stake of 223,506 shares in Paymentus Holdings for an estimated $5.88 million, based on the average closing price during the first quarter, indicating a significant reduction in confidence in the stock as the fund's quarter-end position fell by $7.06 million.
- Portfolio Concentration: As of the end of March, Adams Street Partners maintained a highly concentrated portfolio with only three stocks, where its largest holding, BillionToOne, constituted 52% of its total assets under management, highlighting a risky reliance on a limited number of investments.
- Paymentus Performance Review: Despite Adams Street's exit from Paymentus, the company reported robust growth in its recent earnings release, with first-quarter revenue surging 30.2% year-over-year to $358.4 million and adjusted earnings rising 50% to $0.21 per share, indicating strong operational momentum.
- Market Outlook Analysis: The recent launch of AI-native Service Commerce tools by Paymentus is expected to further drive growth, and while it was not included in the current top investment stocks identified by analysts, its innovative capabilities in electronic bill payment may attract future investor interest.
See More
Investor Perspectives on Silicon Motion and BillionToOne
- Silicon Motion Outlook: Investors express a positive outlook on Silicon Motion Technology (SIMO), with analysts recommending buying during pullbacks despite significant stock volatility, indicating confidence in its long-term growth potential.
- Wynn's Challenges: Wynn Resorts faces significant investment issues in the Gulf region, and while its stock performance has been strong, management indicates a need to observe developments before making decisions, reflecting a cautious approach to market uncertainties.
- Design Therapeutics Risks: Design Therapeutics is viewed as a high-risk investment, with investors needing to be aware of the potential for total loss, although the potential for doubling returns exists, highlighting the market's high uncertainty regarding its future performance.
- BillionToOne Investment Advice: BillionToOne is favored by investors, with analysts suggesting a buy, indicating optimism about its business model and growth prospects, which may attract more investor attention.
See More
Unity Confirm Launches Non-Invasive Prenatal Testing Breakthrough
- Technological Breakthrough: BillionToOne has launched Unity Confirm™, which utilizes its Fetal Cell Capture™ technology to non-invasively capture intact fetal cells, achieving a 100% fetal fraction and significantly enhancing the accuracy and accessibility of prenatal testing.
- Clinical Validation: Unity Confirm demonstrated 100% concordance with known fetal outcomes and invasive diagnostic results across 16 samples, providing a reliable non-invasive confirmation solution for high-risk prenatal screenings and reducing pregnancy risks.
- Market Demand: As non-invasive prenatal testing (NIPT) becomes the standard, Unity Confirm offers a new option for patients who cannot or choose not to undergo invasive testing, bridging the information gap between screening and diagnosis and improving healthcare equity.
- Future Research: BillionToOne is enrolling 1,000 patients in a prospective study to further validate the performance of Unity Confirm, which is expected to have a profound impact on the field of prenatal genetic testing.
See More
Jim Cramer's Insights on Various Stocks
- Joby Aviation Risk Assessment: Joby Aviation is deemed too risky, with analysts advising new investors to be cautious to avoid disappointment from potential stock price drops, which could hinder its ability to attract new investors.
- BillionToOne Potential: Despite the overall poor performance of diagnostic companies, BillionToOne is viewed as a potential winner, with analysts believing its future performance is promising, which may draw more investor interest in its stock.
- Boston Scientific Competitive Pressure: Boston Scientific faces intense competition, with analysts noting that its market position is under threat; however, there is still potential for a rebound, prompting investors to watch for a price bottom before deciding to buy.
- Rocket Lab Investment Opportunity: Rocket Lab is considered a speculative stock worth investing in, with analysts optimistic about its future performance, especially leading up to the SpaceX IPO, which could attract more speculative investments.
See More
Jim Cramer's Insights on Various Stocks
- Automation Company Outlook: Symbiotic is characterized as an automation and robotics firm, and despite competition from Elon Musk, it is seen as having market space; Cramer suggests investors consider buying a few shares for potential gains.
- Planet Labs Price Assessment: Cramer notes that Planet Labs' stock has risen too much, indicating that its current price is unattractive, and advises investors to be cautious and avoid buying at high levels.
- Ollie's Bargain Outlet Concerns: Cramer expresses concern over Ollie's Bargain Outlet's performance, marking its first decline; he plans to conduct further research to understand its future trajectory, demonstrating a commitment to the company.
- Bitcoin Investment Strategy: Cramer mentions that Strategy no longer needs to rely on its products but should invest directly in Bitcoin for more direct exposure, reflecting a keen interest in the cryptocurrency market.
See More
BillionToOne Appoints VP of Medical Affairs for Oncology
- Executive Appointment: BillionToOne has appointed Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development for Oncology, leveraging his over 20 years of experience in cancer care to enhance the strategic growth of the Northstar liquid biopsy portfolio.
- Rich Professional Background: Dr. Chen has held significant positions at leading academic medical centers, including UC Davis and UCLA, and has authored over 300 peer-reviewed publications, demonstrating his deep expertise in cancer research and health policy.
- Driving Technological Innovation: Under Dr. Chen's leadership, BillionToOne aims to advance innovative products like Northstar Select® and Northstar Response®, which are designed to provide personalized treatment options for cancer patients through ultra-sensitive genomic testing, enhancing the precision of clinical decision-making.
- Forward-Looking Strategy: The CEO of BillionToOne stated that Dr. Chen's addition will provide essential expertise to support the company's oncology mission, positioning it to lead in the rapidly evolving molecular diagnostics market.
See More
Adams Street Partners Exits Entire Paymentus Stake for $5.9 Million
- Share Sale Details: Adams Street Partners LLC reported in its SEC filing dated May 15, 2026, that it sold its entire stake of 223,506 shares in Paymentus Holdings for an estimated $5.88 million, based on the average closing price during the first quarter, indicating a significant reduction in confidence in the stock as the fund's quarter-end position fell by $7.06 million.
- Portfolio Concentration: As of the end of March, Adams Street Partners maintained a highly concentrated portfolio with only three stocks, where its largest holding, BillionToOne, constituted 52% of its total assets under management, highlighting a risky reliance on a limited number of investments.
- Paymentus Performance Review: Despite Adams Street's exit from Paymentus, the company reported robust growth in its recent earnings release, with first-quarter revenue surging 30.2% year-over-year to $358.4 million and adjusted earnings rising 50% to $0.21 per share, indicating strong operational momentum.
- Market Outlook Analysis: The recent launch of AI-native Service Commerce tools by Paymentus is expected to further drive growth, and while it was not included in the current top investment stocks identified by analysts, its innovative capabilities in electronic bill payment may attract future investor interest.
See More
Investor Perspectives on Silicon Motion and BillionToOne
- Silicon Motion Outlook: Investors express a positive outlook on Silicon Motion Technology (SIMO), with analysts recommending buying during pullbacks despite significant stock volatility, indicating confidence in its long-term growth potential.
- Wynn's Challenges: Wynn Resorts faces significant investment issues in the Gulf region, and while its stock performance has been strong, management indicates a need to observe developments before making decisions, reflecting a cautious approach to market uncertainties.
- Design Therapeutics Risks: Design Therapeutics is viewed as a high-risk investment, with investors needing to be aware of the potential for total loss, although the potential for doubling returns exists, highlighting the market's high uncertainty regarding its future performance.
- BillionToOne Investment Advice: BillionToOne is favored by investors, with analysts suggesting a buy, indicating optimism about its business model and growth prospects, which may attract more investor attention.
See More
Unity Confirm Launches Non-Invasive Prenatal Testing Breakthrough
- Technological Breakthrough: BillionToOne has launched Unity Confirm™, which utilizes its Fetal Cell Capture™ technology to non-invasively capture intact fetal cells, achieving a 100% fetal fraction and significantly enhancing the accuracy and accessibility of prenatal testing.
- Clinical Validation: Unity Confirm demonstrated 100% concordance with known fetal outcomes and invasive diagnostic results across 16 samples, providing a reliable non-invasive confirmation solution for high-risk prenatal screenings and reducing pregnancy risks.
- Market Demand: As non-invasive prenatal testing (NIPT) becomes the standard, Unity Confirm offers a new option for patients who cannot or choose not to undergo invasive testing, bridging the information gap between screening and diagnosis and improving healthcare equity.
- Future Research: BillionToOne is enrolling 1,000 patients in a prospective study to further validate the performance of Unity Confirm, which is expected to have a profound impact on the field of prenatal genetic testing.
See More
Jim Cramer's Insights on Various Stocks
- Joby Aviation Risk Assessment: Joby Aviation is deemed too risky, with analysts advising new investors to be cautious to avoid disappointment from potential stock price drops, which could hinder its ability to attract new investors.
- BillionToOne Potential: Despite the overall poor performance of diagnostic companies, BillionToOne is viewed as a potential winner, with analysts believing its future performance is promising, which may draw more investor interest in its stock.
- Boston Scientific Competitive Pressure: Boston Scientific faces intense competition, with analysts noting that its market position is under threat; however, there is still potential for a rebound, prompting investors to watch for a price bottom before deciding to buy.
- Rocket Lab Investment Opportunity: Rocket Lab is considered a speculative stock worth investing in, with analysts optimistic about its future performance, especially leading up to the SpaceX IPO, which could attract more speculative investments.
See More
Jim Cramer's Insights on Various Stocks
- Automation Company Outlook: Symbiotic is characterized as an automation and robotics firm, and despite competition from Elon Musk, it is seen as having market space; Cramer suggests investors consider buying a few shares for potential gains.
- Planet Labs Price Assessment: Cramer notes that Planet Labs' stock has risen too much, indicating that its current price is unattractive, and advises investors to be cautious and avoid buying at high levels.
- Ollie's Bargain Outlet Concerns: Cramer expresses concern over Ollie's Bargain Outlet's performance, marking its first decline; he plans to conduct further research to understand its future trajectory, demonstrating a commitment to the company.
- Bitcoin Investment Strategy: Cramer mentions that Strategy no longer needs to rely on its products but should invest directly in Bitcoin for more direct exposure, reflecting a keen interest in the cryptocurrency market.
See More
BillionToOne Appoints VP of Medical Affairs for Oncology
- Executive Appointment: BillionToOne has appointed Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development for Oncology, leveraging his over 20 years of experience in cancer care to enhance the strategic growth of the Northstar liquid biopsy portfolio.
- Rich Professional Background: Dr. Chen has held significant positions at leading academic medical centers, including UC Davis and UCLA, and has authored over 300 peer-reviewed publications, demonstrating his deep expertise in cancer research and health policy.
- Driving Technological Innovation: Under Dr. Chen's leadership, BillionToOne aims to advance innovative products like Northstar Select® and Northstar Response®, which are designed to provide personalized treatment options for cancer patients through ultra-sensitive genomic testing, enhancing the precision of clinical decision-making.
- Forward-Looking Strategy: The CEO of BillionToOne stated that Dr. Chen's addition will provide essential expertise to support the company's oncology mission, positioning it to lead in the rapidly evolving molecular diagnostics market.
See More
